Search Result

Results for "

DOTA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (7) Amino Acid Derivatives (2) Bacterial (1) Biochemical Assay Reagents (46) Carbonic Anhydrase (2) CCR (1) CGRP Receptor (1) CXCR (4) DNA-PK (1) Drug Derivative (3) Drug Intermediate (3) Drug-Linker Conjugates for ADC (2) EGFR (2) FAP (10) Formyl Peptide Receptor (FPR) (1) Glycoprotein VI (1) Hapten (1) Integrin (3) Interleukin Related (2) LDLR (1) Ligands for Target Protein for PROTAC (1) Liposome (1) Melanocortin Receptor (2) MMP (1) Neurokinin Receptor (1) Neurotensin Receptor (1) PARP (1) Peptide-Drug Conjugates (PDCs) (1) Prolyl Endopeptidase (PREP) (1) PROTAC Linkers (5) PSMA (8) Radionuclide-Drug Conjugates (RDCs) (70) Reference Standards (2) Somatostatin Receptor (7) TROP2 (1) VEGFR (1) VISTA (2)
By Research Areas:	Cancer (109) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (10) Neurological Disease (1)
Click Chemistry:	DBCO (1) PROTAC Synthesis (3) Azide (4) Tetrazine (1) Alkynes (2)
Oligonucleotides:	Pegylated Lipids (1)

147

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Click Chemistry

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128890

DOTA-NHS-ester 1 Publications Verification	ADC Linker	Cancer
DOTA-NHS-ester is a linker for affibody molecules and is applied in small animals PET, SPECT, and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for the detection of tumors .

HY-133540

Maleimide-DOTA 2 Publications Verification Maleimido-mono-amide-DOTA	ADC Linker	Inflammation/Immunology Cancer
Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-106244

DOTATATE 3 Publications Verification Oxodotreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-114377

p-SCN-Bn-DOTA 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunoresearch of tumor .

HY-W034551

DOTA-tri(t-butyl ester)	Radionuclide-Drug Conjugates (RDCs)	Others Cancer
DOTA-tri(t-butyl ester) belongs to the DOTA class of chelating agents. DOTA-tri(t-butyl ester) is a key raw material for synthesizing nanospherical magnetic resonance imaging (MRI) contrast agents, which are used in MR angiography and tumor angiogenesis imaging .

HY-131326

DOTA-tris(tBu)ester NHS ester	Biochemical Assay Reagents	Cancer
DOTA-tris(tBu)ester NHS ester is a bifunctional precursor to a DOTA-based chelating agent. DOTA-tris(tBu)ester NHS ester can be used to label primary amines (R-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules, and upon deprotection forms stable complexes with metal ions for applications in molecular imaging .

HY-W087187

DOTAGA-anhydride	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Infection Cancer
DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .

HY-W053583

Tetraxetan 1 Publications Verification DOTA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cancer
Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-W614269

DOTA-GA(tBu)4	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-GA(tBu)4 stabilizes the attachment of radiometals to ligands. DOTA-GA(tBu)4 improves the biodistribution of radiolabeled second-generation Affibody molecules by increasing their net negative charge and reducing hepatic uptake, leading to enhanced tumor-to-blood and tumor-to-liver ratios. DOTA-GA(tBu)4 targets HER2>-expressing breast and gastrointestinal cancer .

HY-159181

*p-NCS-Bz-DOTA-GA*	Biochemical Assay Reagents	Others
p-NCS-Bz-DOTA-GA is a bifunctional chelator. p-NCS-Bz-DOTA-GA can be used as a versatile linker in targeted molecular imaging for both PET/SPECT and MRI applications .

HY-P5126

DOTA-LM3 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5128

DOTA-JR11 1 Publications Verification Satoreotide tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106244A

DOTATATE acetate 3 Publications Verification Oxodotreotide acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-W1124925

DOTA-GPC3 targeting peptide 2	Radionuclide-Drug Conjugates (RDCs) Glycoprotein VI	Cancer
DOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with K_d of 0.3 nM. DOTA-GPC3 targeting peptide 2 is composed of DOTA and GPC3 targeting peptide 2. DOTA-GPC3 targeting peptide 2 can be labeled with radioactive elements .

HY-164569

*NH2 DOTA-GA*	Radionuclide-Drug Conjugates (RDCs)	Cancer
NH2 DOTA-GA is a DOTA-based metal chelator that can be used to prepare radionuclide drug conjugates (RDCs) whose carboxylic acid groups can complex metal ions, for example, NH2 DOTA-GA complexes Gd(III) ions.

HY-156038

(S)-p-SCN-Bn-DOTA	Biochemical Assay Reagents	Others
(S)-p-SCN-Bn-DOTA is a bifunctional chelator (BFC), a macrocyclic DOTA derivative for tumor pretargeting. (S)-p-SCN-Bn-DOTA can be used for the conjugation of peptides and radionuclides, such as as a linker for In-111 labeled radioimmunoconjugates (RICs) for single photon emission tomography (SPECT) and in vitro biodistribution studies .

HY-140752

DOTA-PEG5-azide	PROTAC Linkers	Cancer
DOTA-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DOTA-PEG5-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-P11287A

DOTA-Pep-1L TFA	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L TFA is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L TFA specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L TFA yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L TFA can be used for PET imaging, tumor targeting and glioma research .

HY-157977

DOTA-GA-maleimide	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) MMP	Cancer
DOTA-GA-maleimide is a bifunctional chelator with protein conjugation and radiometal chelation capabilities. DOTA-GA-maleimide forms stable complexes with ¹¹¹In and conjugates with proteins via maleimide chemistry. DOTA-GA-maleimide conjugates with LFn, enabling ¹¹¹In radiolabeling of LFn through direct or pre-labeling strategies. Radiolabeled LFn is applicable to MMP activity imaging studies. DOTA-GA-maleimide is used in cancer research .

HY-D2363

DOTA.SA.FAPi TFA	Radionuclide-Drug Conjugates (RDCs) FAP Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA is a selective FAP inhibitor with an IC₅₀ value of 0.9 nM against FAP. DOTA.SA.FAPi TFA forms stable complexes with ⁶⁸Ga and serves as a PET radiotracer for preclinical imaging of FAP-expressing tumors. DOTA.SA.FAPi TFA can be used in the research of colorectal adenocarcinoma and various other cancers .

HY-W539916

Azido-mono-amide-DOTA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-P2112

DOTA-NOC DOTA-Nal3-octreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Others
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5126A

DOTA-LM3 TFA 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-100133A

DOTA-ADIBO TFA	Integrin	Cancer
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

HY-W755033

NH2-PEG4-DOTA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
NH2-PEG4-DOTA is a bifunctional DOTA chelator with one carboxyl group modified by NH2-PEG4, possessing both a metal-binding domain and a chemically reactive functional group. NH2-PEG4-DOTA can be used for time-resolved fluorescence assays .

HY-164574

BCN-DOTA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
BCN-DOTA is a cyclooctyne-linked DOTA chelator. BCN-DOTA integrates BCN and DOTA, enabling conjugation with azide-functionalized groups via the click chemistry properties of BCN, while binding to metal ions through the coordination capacity of DOTA. BCN-DOTA can serve as a radionuclide-drug conjugate (RDC) to target specific biomolecules, cells or tissues after radiolabeling with zirconium-89. BCN-DOTA is applicable to research related to PET imaging and targeted therapy .

HY-W678394

DOTA-Thiol	Biochemical Assay Reagents	Others
DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.

HY-P6351

*c(avb6)-DOTA* TFA**	Integrin	Cancer
c(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with DOTA chelator. The Lu(III) complex of c(avb6)-DOTA TFA has a comparable affinity for αvβ6 integrin (IC₅₀=0.8 nM) and can be used as a tumor diagnostic .

HY-164731

Mal-PEG12-DOTA	ADC Linker	Cancer
Mal-PEG12-DOTA is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-P10729A

DOTA-Bombesin (1-14) TFA	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Bombesin (1-14) TFA is composed of chelator DOTA and Bombesin (HY-P0195). DOTA-Bombesin (1-14) TFA is used for research of cancer through combination with radioactive elements. DOTA-Bombesin (1-14)TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-139564

DOTA Zoledronate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases .

HY-140314

DOTA-PEG5-C6-DBCO	PROTAC Linkers	Cancer
DOTA-PEG5-C6-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DOTA-PEG5-C6-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-P10273A

DOTA-Octreotide TFA	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P11287

DOTA-Pep-1L	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research .

HY-P10741

DOTA-EB-TATE	Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Somatostatin Receptor	Cancer
DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-W782078

Butyne-DOTA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.

HY-W717779

4-Aminobutyl-DOTA	Biochemical Assay Reagents	Others
4-Aminobutyl-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA can be used for conjugation of peptides and radionuclides.

HY-175613

DOTA-ALB-02	FAP	Cancer
DOTA-ALB-02 is an albumin-bound FAP inhibitor (FAPI) ligand. DOTA-ALB-02 labeled with ¹⁷⁷Lu has a high FAP-binding affinity and enhanced tumor uptake and retention with a significant tumor/nontarget ratio. DOTA-ALB-02 can be used for PET/CT and SPECT/CT imaging of cancers, especially late-stage cancers .

HY-128890B

DOTA-NHS-ester TFA 1 Publications Verification	ADC Linker Biochemical Assay Reagents	Cancer
DOTA-NHS-ester (TFA) is used as a linker for affibody molecules, and it can be employed in small animal positron emission tomography (PET), single photon emission computed tomography (SPECT), and CT scanning. DOTA-NHS-ester can be used to label radiotracers or imaging probes for tumor detection .

HY-140008

DOTA-PEG5-amine	PROTAC Linkers	Cancer
DOTA-PEG5-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .

HY-P10732

DOTA-cyclo(RGDfK)	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-cyclo(RGDfK) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-177459

DOTA-2P(FAPI)2	FAP	Cancer
DOTA-2P(FAPI)2 is a dimeric FAP (fibroblast activation protein) that can be used as a PET imaging agent and a tracer for tumor therapy .

HY-158072

DOTAM-NHS-ester	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTAM-NHS-ester is a bifunctional chelator and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-NHS-ester combines the efficient metal chelating ability of DOTAM macrocyclic ligands with the bioconjugation function of NHS ester active groups, and can be widely used in the biomedical field for metal labeling, molecular imaging and drug delivery development .

HY-164732

*Fmoc-Lys(DOTA)-OH*	Amino Acid Derivatives Biochemical Assay Reagents	Others
Fmoc-Lys (DOTA)-OH is an Fmoc-protected Lysine derivative with metal-chelating properties, containing the macrocyclic chelator DOTA. Fmoc-Lys (DOTA)-OH undergoes metallation with Tb or Lu. Fmoc-Lys (DOTA)-OH utilizes metal coordination to protect the carboxyl groups of DOTA. Fmoc-Lys (DOTA)-OH can be used in solid-phase peptide synthesis research .

HY-170779

DOTA-NI-FAPI-04	FAP	Cancer
DOTA-NI-FAPI-04 is a FAP inhibitor (IC₅₀ = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .

HY-164577

*BCN-DOTA-GA*	Radionuclide-Drug Conjugates (RDCs)	Cancer
BCN-DOTA-GA is a cyclooctyne-linked DOTA chelator that can be labeled with radioactive zirconium-89 and used as a radionuclide-labeled drug conjugate (RDC) to target specific biomolecules, cells or tissues.

HY-W451440

*Butyne-DOTA-tris(t-butyl ester)*	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-P11026

DOTA-TMVP1446 DOTA-PEG4-TMVP1446	VEGFR	Cancer
DOTA-TMVP1446 is a VEGFR-3 targeting peptide. DOTA-TMVP1446 labeled with ⁶⁸Ga accurately detectes the status of lymph node metastasis, even in micrometastatic tumors, in the B16-F10 tumor mice model. DOTA-TMVP1446 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .

HY-140753

DOTA-(t-butyl)3-PEG5-azide	PROTAC Linkers	Cancer
DOTA-(t-butyl)3-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DOTA-(t-butyl)3-PEG5-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-W053583R

Tetraxetan (Standard) DOTA (Standard)	Biochemical Assay Reagents Reference Standards Radionuclide-Drug Conjugates (RDCs)	Cancer
Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

Cat. No.	Product Name	Type

HY-133540G

Maleimide-DOTA Maleimido-mono-amide-DOTA	Fluorescent Dyes
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-W087187G

DOTAGA-anhydride

Fluorescent Dyes

DOTAGA-anhydride (GMP) is DOTAGA-anhydride (HY-W087187) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .

Cat. No.	Product Name	Type

HY-W053583

Tetraxetan

1 Publications Verification

DOTA

Biochemical Assay Reagents

Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-159181

*p-NCS-Bz-DOTA-GA*	Biochemical Assay Reagents
p-NCS-Bz-DOTA-GA is a bifunctional chelator. p-NCS-Bz-DOTA-GA can be used as a versatile linker in targeted molecular imaging for both PET/SPECT and MRI applications .

HY-156038

(S)-p-SCN-Bn-DOTA	Biochemical Assay Reagents
(S)-p-SCN-Bn-DOTA is a bifunctional chelator (BFC), a macrocyclic DOTA derivative for tumor pretargeting. (S)-p-SCN-Bn-DOTA can be used for the conjugation of peptides and radionuclides, such as as a linker for In-111 labeled radioimmunoconjugates (RICs) for single photon emission tomography (SPECT) and in vitro biodistribution studies .

HY-W539916

Azido-mono-amide-DOTA	Biochemical Assay Reagents
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-100133A

DOTA-ADIBO TFA	Biochemical Assay Reagents
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

HY-W749603

*Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester)*	Biochemical Assay Reagents
Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester) is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W678394

DOTA-Thiol	Biochemical Assay Reagents
DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.

HY-48876

p-NH2-Bn-DOTA	Biochemical Assay Reagents
p-NH2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA can be used for conjugation of peptides and radionuclides.

HY-W782078

Butyne-DOTA	Biochemical Assay Reagents
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.

HY-W717779

4-Aminobutyl-DOTA	Biochemical Assay Reagents
4-Aminobutyl-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA can be used for conjugation of peptides and radionuclides.

HY-158072

DOTAM-NHS-ester	Biochemical Assay Reagents
DOTAM-NHS-ester is a bifunctional chelator and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-NHS-ester combines the efficient metal chelating ability of DOTAM macrocyclic ligands with the bioconjugation function of NHS ester active groups, and can be widely used in the biomedical field for metal labeling, molecular imaging and drug delivery development .

HY-172699

DSPE-PEG2000-ANG	Biochemical Assay Reagents
DSPE-PEG2000-ANG is a conjugate of DSPE-PEG2000-MAL and Angiopep-2. Angiopep-2 is a peptide ligand that targets LRP-1. DSPE-PEG2000-ANG is used to synthesize gadolinium-boron bifunctionalized lipid nanoparticles BPA-F&DOTA-Gd@LIPO-ANG with blood-brain barrier and glioma targeting properties .

HY-W451440

*Butyne-DOTA-tris(t-butyl ester)*	Biochemical Assay Reagents
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-W053583R

Tetraxetan (Standard)

DOTA (Standard)

Biochemical Assay Reagents

Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-131673A

(S)-p-SCN-Bn-TCMC hydrochloride	Biochemical Assay Reagents
(S)-p-SCN-Bn-TCMC (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (S)-p-SCN-Bn-TCMC (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W088413

DOTA-amide	Biochemical Assay Reagents
DOTA-amideis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-amide can be used for conjugation of peptides and radionuclides.

HY-133540G

Maleimide-DOTA Maleimido-mono-amide-DOTA	Biochemical Assay Reagents
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-128890A

DOTA-NHS-ester hexafluorophosphate TFA	Biochemical Assay Reagents
DOTA-NHS-ester (hexafluorophosphate TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-NHS-ester (hexafluorophosphate TFA) can be used for conjugation of peptides and radionuclides.

HY-W250844A

DO3A trisodium	Biochemical Assay Reagents
DO3A (trisodium)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO3A (trisodium) can be used for conjugation of peptides and radionuclides.

HY-W087187G

DOTAGA-anhydride

Biochemical Assay Reagents

HY-W802013

DOTA-4AMP	Biochemical Assay Reagents
DOTA-4AMPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-4AMP can be used for conjugation of peptides and radionuclides.

HY-W088413A

DOTA-amide dihydrate	Biochemical Assay Reagents
DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to HER2 and can be used to detect bone metastases, which are common in prostate cancer .

HY-W460274

*4-Aminobutyl-DOTA-tris(t-butyl ester)*	Biochemical Assay Reagents
4-Aminobutyl-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-W250929

*Maleimido-mono-amide-DOTA-tris(t-Bu ester)*	Biochemical Assay Reagents
Maleimido-mono-amide-DOTA-tris(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Maleimido-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W782075

p-NO2-Bn-DOTA	Biochemical Assay Reagents
p-NO2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NO2-Bn-DOTA can be used for conjugation of peptides and radionuclides.

HY-W717760

*p-NH2-Bn-DOTA-tetra(t-Bu ester)*	Biochemical Assay Reagents
p-NH2-Bn-DOTA-tetra(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA-tetra(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-158065

*Azido-mono-amide-DOTA-tris(t-Bu ester)*	Biochemical Assay Reagents
Azido-mono-amide-DOTA-tris(t-Bu ester) is a biochemical assay reagent, and is a click chemistry reagent .

HY-158077

(R)-tetraMe-Tetraxetan (R)-tetraMe-DOTA	Biochemical Assay Reagents
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.

HY-173383

*DOPE-DOTA* sodium** 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N- tetraazacyclododecane-N-tetraacetic acid, sodium salt	Biochemical Assay Reagents
DOPE-DOTA sodium is a chelated lipid that serves as a key contrast agent in magnetic resonance imaging (MRI). DOPE-DOTA sodium can be used for cancer, blood-brain barrier disruption, abnormalities such as aneurysms or plaque buildup, inflammation in arthritis, and liver function and lesions study

HY-173384

*DSPE-DOTA* sodium** 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- tetraazacyclododecane-N-tetraacetic acid, sodium salt	Biochemical Assay Reagents
DSPE-DOTA sodium (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- tetraazacyclododecane-N-tetraacetic acid, sodium salt) is a chelating lipid used as a key contrast agent in magnetic resonance imaging (MRI). DSPE-DOTA sodium can be used for imaging detection of tumors, neurological and inflammatory diseases .

HY-W726767

DO2A	Biochemical Assay Reagents
DO2Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO2A can be used for conjugation of peptides and radionuclides.

HY-W782081

p-SCN-Bn-oxo-DO3A	Biochemical Assay Reagents
p-SCN-Bn-oxo-DO3Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-SCN-Bn-oxo-DO3A can be used for conjugation of peptides and radionuclides.

HY-W782080

p-NH2-Bn-oxo-DO3A	Biochemical Assay Reagents
p-NH2-Bn-oxo-DO3Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-oxo-DO3A can be used for conjugation of peptides and radionuclides.

Cat. No.	Product Name	Target	Research Area

HY-106244

DOTATATE 3 Publications Verification Oxodotreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10761

DPI-4452	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC₅₀ for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5126

DOTA-LM3 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5128

DOTA-JR11 1 Publications Verification Satoreotide tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106244A

DOTATATE acetate 3 Publications Verification Oxodotreotide acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-W1124925

DOTA-GPC3 targeting peptide 2	Radionuclide-Drug Conjugates (RDCs) Glycoprotein VI	Cancer
DOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with K_d of 0.3 nM. DOTA-GPC3 targeting peptide 2 is composed of DOTA and GPC3 targeting peptide 2. DOTA-GPC3 targeting peptide 2 can be labeled with radioactive elements .

HY-P11287A

DOTA-Pep-1L TFA	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L TFA is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L TFA specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L TFA yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L TFA can be used for PET imaging, tumor targeting and glioma research .

HY-D2363

DOTA.SA.FAPi TFA	Radionuclide-Drug Conjugates (RDCs) FAP Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA is a selective FAP inhibitor with an IC₅₀ value of 0.9 nM against FAP. DOTA.SA.FAPi TFA forms stable complexes with ⁶⁸Ga and serves as a PET radiotracer for preclinical imaging of FAP-expressing tumors. DOTA.SA.FAPi TFA can be used in the research of colorectal adenocarcinoma and various other cancers .

HY-P2112

DOTA-NOC DOTA-Nal3-octreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Others
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-153549

Pentixafor 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5126A

DOTA-LM3 TFA 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .

HY-P2336A

CCZ01048 TFA 3 Publications Verification	Melanocortin Receptor	Cancer
CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .

HY-P2218

Anditixafortide	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P6351

*c(avb6)-DOTA* TFA**	Integrin	Cancer
c(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with DOTA chelator. The Lu(III) complex of c(avb6)-DOTA TFA has a comparable affinity for αvβ6 integrin (IC₅₀=0.8 nM) and can be used as a tumor diagnostic .

HY-P10729A

DOTA-Bombesin (1-14) TFA	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Bombesin (1-14) TFA is composed of chelator DOTA and Bombesin (HY-P0195). DOTA-Bombesin (1-14) TFA is used for research of cancer through combination with radioactive elements. DOTA-Bombesin (1-14)TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10273A

DOTA-Octreotide TFA	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P11287

DOTA-Pep-1L	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research .

HY-P10239

Tyr3-Octreotate	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC₅₀ value of 1.3 nM against sst2 when labeled with [ ¹¹¹In-DTPA], and an IC₅₀ value of 1.6 nM against sst2 when labeled with [ ⁹⁰Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with ¹⁷⁷Lu or ⁹⁰Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors .

HY-P10741

DOTA-EB-TATE	Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Somatostatin Receptor	Cancer
DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P11026

DOTA-TMVP1446 DOTA-PEG4-TMVP1446	VEGFR	Cancer
DOTA-TMVP1446 is a VEGFR-3 targeting peptide. DOTA-TMVP1446 labeled with ⁶⁸Ga accurately detectes the status of lymph node metastasis, even in micrometastatic tumors, in the B16-F10 tumor mice model. DOTA-TMVP1446 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .

HY-P10444

DOTA Conjugated JM#21 derivative 7	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5297

DOTA-CXCR4-L	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-W046355

Fmoc-D-Dap(Boc)-OH	Radionuclide-Drug Conjugates (RDCs) Amino Acid Derivatives	Others
Fmoc-D-Dap(Boc)-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize bioactive peptide mimetics, such as DOTA-modified peptides and their metal chelates with cancer diagnostic effects .

HY-P10781

PSMA-D5	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
PSMA-D5 has a binding affinity for PSMA with a K_i of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([68Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. PSMA-D5 ([68Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10307

DOTA-ubiquicidin (29–41)	Radionuclide-Drug Conjugates (RDCs) Bacterial	Infection
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ ⁶⁸Ga]Ga-DOTA-Ubiquicidin_29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10273

DOTA-Octreotide	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P11293

DOTA-GGNle-CycMSHhex	Melanocortin Receptor	Cancer
DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .

HY-P11254

DOTA-FAPT	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-FAPT is a novel targeting FAP tracer. DOTA-FAPT can be radiolabeled with gallium-68 and lutetium-177. DOTA-FAPT can be used for PET imaging studies of cancer-associated fibroblasts .

HY-P11257

DOTA-BP1	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-BP1 is a DOTA-modified BP1 (BCMA-targeting peptide). DOTA-BP1 can be radiolabeled with [ ⁶⁸Ga]Ga to produce a BCMA-targeting PET tracer. DOTA-BP1 can be used in the research of detecting BCMA in multiple myeloma .

HY-P11253

DOTA-Bn-CA-170	VISTA	Inflammation/Immunology
DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a K_d value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [ ⁶⁸Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy .

HY-158266

DOTA-PSMA-EB-01 LNC1003	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC₅₀= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of ¹⁷⁷Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10951

(R)-Zadavotide guraxetan (R)-PSMA I&T; (R)-PNT-2002	PSMA	Cancer
Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .

HY-P10743

BQ7876	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11252

DOTA-CA-170	Radionuclide-Drug Conjugates (RDCs) VISTA	Cancer
DOTA-CA-170 is a DOTA-modified VISTA targeting agent CA-170. DOTA-CA-170 can be radiolabeled. DOTA-CA-170 can be used in the research of visualizing and distinguishing VISTA expression .

HY-159526

Adarulatide tetraxetan DOTA-AE105	Biochemical Assay Reagents	Others
Copper adarulatidum tetraxetanum (Copper adarulatide tetraxetan) is a diagnostic imaging agent .

HY-P11613

DOTA-WC8	EGFR	Cancer
DOTA-WC8 is a HER2-targeting peptide probe with a K_D of 61.20 nM. ⁶⁸Ga-labeled DOTA-WC8 serves as a PET imaging agent for the specific identification of HER2-positive breast cancer. DOTA-WC8 is applicable to breast cancer-related research .

HY-P11553B

DOTA-ECL1i	Radionuclide-Drug Conjugates (RDCs) CCR	Cardiovascular Disease Inflammation/Immunology Cancer
DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with ⁶⁸Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer .

HY-P11488

*JR11-PEG3-DOTA-PSMA-03*	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA	Cancer
JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC₅₀ s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [ ⁶⁸Ga]. [ ⁶⁸Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .

HY-P3335

SU015 DOTA-RGDfK dimer	Integrin Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
SU015 (DOTA-RGDfK dimer) is a Integrin α_vβ₅ and α_vβ₃ antagonist. SU015 exhibits comparable affinity for α_vβ₅ and α_vβ₃, with relatively higher potency and specificity compared to other integrins. SU015 inhibits α_vβ₃-mediated cell adhesion to fibrinogen, α_vβ₃-mediated adhesion of activated platelets to osteopontin, and α_vβ₅-mediated cell adhesion to vitronectin. SU015 shows potent inhibitory effects on FGF2-induced angiogenesis in the CAM model. SU015 carries a linker arm available for radioisotope conjugation, and acts as a target-specific radioreagent when labeled with ⁹⁰Y (i.e., RP697) or ¹⁷⁷Lu (i.e., RP688). SU015 can be used in studies related to tumor metastasis and tumors .

HY-P3413

H-Glu-Pro-Leu-Gln-Leu-Lys-Met-OH	Peptides	Inflammation/Immunology
H-Glu-Pro-Leu-Gln-Leu-Lys-Met-OH (EM7) is a linear mesenchymal stem cells (MSC)-specific peptide. H-Glu-Pro-Leu-Gln-Leu-Lys-Met-OH can be used to prepare Gd-DOTA-peptide complexes .

HY-P11845

DOTA-NT-20.3-IPBA	Radionuclide-Drug Conjugates (RDCs) Neurotensin Receptor	Cancer
DOTA-NT-20.3-IPBA is a Neurotensin receptor 1 (NTR1)-targeting albumin binder with specific high-affinity binding to NTR1. DOTA-NT-20.3-IPBA is formed by the conjugation of DOTA-NT-20.3 and IPBA. DOTA-NT-20.3-IPBA can be used for positron emission tomography (PET) imaging following labeling with [ ⁶⁸Ga]Ga .

HY-P11602

DOTA-C1-FAP-2286	FAP	Cancer
DOTA-C1-FAP-2286 is a cysteic acid-modified fibroblast activation protein (FAP)-targeting radioligand. DOTA-C1-FAP-2286 binds competitively to FAP with an IC₅₀ of 127.64 nM. DOTA-C1-FAP-2286 is targeted accumulation in FAP-expressing cells and exhibits accelerated renal clearance. DOTA-C1-FAP-2286 can be used as a PET/CT tracer in cancer .

HY-P11591

PDI2 PSMA-DOTA-PEI2	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer .

HY-P11769

RM2	CGRP Receptor	Cancer
RM2 is a GRPr antagonist. RM2 selectively binds to GRPr, blocks agonist-induced receptor internalization, and inhibits agonist-triggered intracellular calcium mobilization. RM2 can be used in studies related to prostate cancer .

HY-P3413A

H-Glu-Pro-Leu-Gln-Leu-Lys-Met-OH acetate	Peptides	Others
H-Glu-Pro-Leu-Gln-Leu-Lys-Met-OH (EM7) acetate is a linear mesenchymal stem cell (MSC) specific peptide. H-Glu-Pro-Leu-Gln-Leu-Lys-Met-OH acetate can be used to prepare Gd-DOTA-peptide complexes.

HY-P11718

cFLFLF	Formyl Peptide Receptor (FPR) Radionuclide-Drug Conjugates (RDCs)	Inflammation/Immunology
cFLFLF is a FPR-specific peptide. cFLFLF is sequentially conjugated with a bifunctional polyethylene glycol moiety (PEG, 3.4 kD) and a DOTA through a lysine (K) spacer and finally labeled with ⁶⁴Cu-CuCl₂ to form cFLFLFKPEG- ⁶⁴Cu. cFLFLFKPEG- ⁶⁴Cu is a neutrophil-specific PET imaging agent .

HY-P11590

WGYRGFYC	EGFR	Cancer
WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a K_D of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99239

Rosopatamab HUJ-591; TLX591	PSMA Radionuclide-Drug Conjugates (RDCs)	Cancer
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( ¹⁷⁷Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .

HY-P992367

hIMB1636	TROP2	Cancer
hIMB1636 is a humanized monoclonal antibody targeting Trop2. By binding to the conformational Trop2 epitope, hIMB1636 regulates related signaling pathways, triggers lysosomal endocytosis, and further induces apoptosis, cell cycle arrest, and antibody-dependent cellular cytotoxicity. hIMB1636 effectively inhibits tumor cell proliferation, migration and in vivo tumor growth, and also exerts bystander killing effect and mediates long-term retention. hIMB1636 can be conjugated with NOTA/DOTA for radiolabeling to enable immuno-PET imaging, or prepared as hIMB1636-LDP-AE to significantly inhibit the growth of breast cancer and lung cancer xenografts .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W007656

Cyclen	Structural Classification Natural Products Classification of Application Fields Other Diseases Plants Menispermaceae Disease Research Fields Stephania japonica (Thunb.) Miers Source Classification	Biochemical Assay Reagents
Cyclen is a macrocyclic tetraamine chelating agent. Cyclen is the aza analogue of crown ether, used as a precursor for MRI contrast agents, and is an intermediate for the preparation of effective macrocyclic chelates. Cyclen is employed as a structural regulator through interfacial polymerization of polyethleneimine (PEI) and trimesoyl chloride (TMC) to develop polyamide NF membrane with efficient Li ⁺/Mg ²⁺ separation performance. Cyclen has specific cavity structure and exhibits selective coordination properties for Li ⁺ ions ^[1][2].

Cat. No.	Product Name		Classification

HY-140752

DOTA-PEG5-azide		Azide PROTAC Synthesis
DOTA-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DOTA-PEG5-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-W539916

Azido-mono-amide-DOTA		Azide
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-140314

DOTA-PEG5-C6-DBCO		DBCO PROTAC Synthesis
DOTA-PEG5-C6-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DOTA-PEG5-C6-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-W782078

Butyne-DOTA		Alkynes
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.

HY-W451440

*Butyne-DOTA-tris(t-butyl ester)*		Alkynes
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-140753

DOTA-(t-butyl)3-PEG5-azide		PROTAC Synthesis Azide
DOTA-(t-butyl)3-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DOTA-(t-butyl)3-PEG5-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-180447

Tz-Ph-PEG4-NH-DOTA		Tetrazine
Tz-Ph-PEG4-NH-DOTA (Compound 10) is a 1,2,4,5-tetrazine (Tz) derivative. Tz-Ph-PEG4-NH-DOTA can be used in PET imaging and tumor research .

HY-158065

*Azido-mono-amide-DOTA-tris(t-Bu ester)*		Azide
Azido-mono-amide-DOTA-tris(t-Bu ester) is a biochemical assay reagent, and is a click chemistry reagent .

Cat. No.	Product Name		Classification

HY-172699

DSPE-PEG2000-ANG		Pegylated Lipids
DSPE-PEG2000-ANG is a conjugate of DSPE-PEG2000-MAL and Angiopep-2. Angiopep-2 is a peptide ligand that targets LRP-1. DSPE-PEG2000-ANG is used to synthesize gadolinium-boron bifunctionalized lipid nanoparticles BPA-F&DOTA-Gd@LIPO-ANG with blood-brain barrier and glioma targeting properties .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W087187G

DOTAGA-anhydride	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTAGA-anhydride (GMP) is DOTAGA-anhydride (HY-W087187) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .

HY-133540G

Maleimide-DOTA Maleimido-mono-amide-DOTA	ADC Linker	Inflammation/Immunology Cancer
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

DOTA

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products